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SUMMARY We recently identified lipocalin2 (LCN2) as being upregulated in ovarian can-
cer cell lines. The purpose of this study was to validate LCN2 upregulation in ovarian cancers
and to investigate its potential as a serum biomarker. We assayed LCN2 expression in ovar-
ian cancers using real-time PCR and IHC. To evaluate the potential of LCN2 as a biomarker,
we measured serum LCN2 levels in 54 ovarian cancers, 15 borderline and 53 benign ovarian
tumors, and 90 healthy controls. SYBR green PCR and IHC showed LCN2 overexpression in
ovarian cancers. LCN2 immunoreactivity was significantly associated with tumor differentia-
tion (p50.009), as well-differentiated tumors showed the highest LCN2 expression. Serum
LCN2 level in ovarian cancer was significantly higher than in the other study groups
(p,0.001), and in accordance with IHC results, it also correlated with tumor differentiation,
with well-differentiated tumors having the highest value. The sensitivity and specificity of
LCN2 in detecting ovarian cancer was 72.2% and 50.4%, respectively. By Cox univariate
analysis, LCN2 positivity was an independent prognostic factor for overall survival (hazard
ratio 5 1.47, p50.012). In conclusion, LCN2 expressions are upregulated and related to tu-
mor differentiation in ovarian cancers and should be included in future research assessing






OVARIAN CANCER is the fifth leading cause of cancer
deaths among women, and it is the most common cause
among gynecological malignancies (Jemal et al. 2007).
The high mortality rate of ovarian cancer results from
the high percentage of cases diagnosed at an advanced
stage, which is because of the relatively asymptomatic
nature of early-stage disease and the lack of adequate
screening tests. When ovarian cancer is diagnosed in
its early stage and is still organ confined, the 5-year sur-
vival rate exceeds 90%. Unfortunately, only 19% of all
ovarian cancers are diagnosed at this stage. Therefore,
an adequate early detection screening for ovarian can-
cer could greatly improve patient survival.
Use of serum markers for early detection of ovarian
cancer has largely focused on CA125, a heavily glyco-
sylated high-molecular-weight mucin (MUC16) (Yin
et al. 2002). However, the usefulness of CA125 as a
biomarker for early diagnosis is limited by the fact that
CA125 exhibits a sensitivity of ,60% in early-stage
disease (Jacobs and Menon 2004). Aside from limited
sensitivity, serum CA125 is elevated by benign gyne-
cological conditions such as benign ovarian tumors,
uterine fibroids, adenomyosis, and inflammation of
the peritoneum. In recent years, numerous potential
biomarkers of ovarian cancer have been identified and
evaluated alone or in combination with CA125 and/or
other markers (Gagne et al. 2005; Mok et al. 2007; Cho
et al. 2009). Microarray technology permits analysis of
expression levels of thousands of genes and is widely
used to identify new biomarkers for the early detection
of cancer (Wong et al. 2001; Raetz andMoos 2004). In a
previous cDNA microarray analysis (Macrogen; Seoul,
Korea) using serous ovarian cancer cell line, YDOV-
157, and three human ovarian surface epithelial (HOSE)
cells, we showed that lipocalin2 (LCN2) had an ovarian
cancer/HOSE ratio of 160, suggesting its expression is
upregulated in ovarian cancers (Cho et al. 2008).
LCN2, also known variously as neutrophil gelatinase-
associated lipocalin (NGAL), oncogene 24p3, and neu-
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related lipocalin (NRL), is a 24-kDa secretory glycopro-
tein that was originally identified in mouse kidney cells
and is stored in human neutrophil granules (Kjeldsen
et al. 1993). Although the primary function of lipocalin
is thought to relate to the transport of small ligands,
they have been implicated in a variety of functions such
as iron trafficking and induction of apoptosis (Devireddy
et al. 2001; Yang et al. 2002). Recently, it was suggested
that LCN2 may scavenge bacterial products at sites of
infection. Several inflammatory stimuli, such as lipo-
polysaccharides and interleukin (IL)-1b, can markedly
induce LCN2 expression and secretion in tissues ex-
posed to microorganisms (Liu and Nilsen-Hamilton
1995). LCN2 limits bacterial growth by sequestering
the iron-laden sideophore. Furthermore, LCN2 has
become of interest to cancer researchers because its
expression changes in colorectal (Nielsen et al. 1996),
breast (Stoesz et al. 1998), and pancreatic cancers
(Furutani et al. 1998), and LCN2 was identified as an
independent poor prognostic factor in breast cancer pa-
tients (Bauer et al. 2008). In this study, we investigated
LCN2 overexpression in ovarian cancer cell lines and
cancer tissues. We also measured serum LCN2 levels
and evaluated the clinical relevance of LCN2 as a diag-
nostic and prognostic marker for ovarian cancer.
Materials and Methods
Cell Lines
A total of six ovarian cancer cell lines were developed
either from malignant ascites or from tissues of solid
tumors. Eight HOSE cell lines were obtained by scrap-
ing the surfaces of healthy ovaries. The ovarian can-
cer cell lines used in this experiment were YDOV-13
(which originated from a malignant Brenner tumor);
YDOV-105, YDOV-139, YDOV-157, and YDOV-161
(which originated from serous cystadenocarcinomas);
and YDOV-151 (which originated from a mucinous
cystadenocarcinoma). This study was approved by the
institutional review board of Yongdong Severance
Hospital, and informed consent was obtained from
each patient before sample collection. All cell lines were
established in the laboratory of Obstetrics and Gynecol-
ogy, Yongdong Severance Hospital, Seoul, Korea.
Biosamples
Paraffin-embedded samples of ovarian cancer (n561),
borderline ovarian tumors (n59), benign ovarian tu-
mors (n511), and healthy tissue (n510) were collected
between April 2001 and May 2007 and stored at the
Yongdong Severance Hospital pathology department
archives. Serum samples (n5122) and fresh frozen tis-
sues (n512) from a different group of patients were ob-
tained from women who underwent elective surgery
for an ovarian tumor at the Yongdong Severance Hos-
pital between May 2004 and July 2007. Blood samples
of case groups (n5122) were collected 24 hr or less be-
fore surgery by peripheral venous puncture. Control
serum specimens (n590) were obtained from patients
undergoing a routine health examination at Yongdong
Severance Hospital between October 2005 and June
2006. All blood samples were centrifuged at 1500 3 g
at 4C for 15 min. The separated serum was removed,
aliquoted, and stored at280C for future analysis. Fresh
tumor specimens were obtained at the time of surgery,
were snap frozen in liquid nitrogen, and were stored at
280C. None of the included patients had a prior diag-
nosis of cancer or had received chemotherapy or sur-
gery for the present disease. Healthy controls had no
history of cancer or gynecological disease and no ab-
normalities as assessed by laboratory examinations or
gynecological sonography. All ovarian cancer patients
were surgically staged according to the International
Federation of Gynecology andObstetrics (FIGO) staging
system. All FIGO Stage I/II ovarian cancer patients had
pelvic and para-aortic lymph node dissection accord-
ing to the National Comprehensive Cancer Network
(NCCN) clinical practice guidelines.
SYBR Green Real-time PCR
The SNU840 cell line was purchased from the Korean
Cell Line Bank (KCLB; Seoul, Korea), and SKOV3,
TOV112D, OVCA429, and RMUG-S cell lines were
purchased from the American Type Culture Collection
(ATCC; Manassas, VA). Cells were maintained in
DMEM/F12 supplemented with 10% FBS in the pres-
ence of 5% CO2 at 37C in a humidified incubator.
SYBR green real-time PCR was used to analyze cell
lines and fresh tissues. Total RNA was extracted from
8 HOSE cell lines (HOSE 10, 15 186, 198, 201, 213,
216, and 225), 4 borderline ovarian tumor tissues
(3 serous and 1 mucinous), 11 ovarian cancer cell lines
(SKOV3, TOV112D, OVCA429, RMUG-S, SNU840,
and YDOV-13, -105, -139, -151, -157, and -161), and
7 ovarian cancer tissues (7 serous) using the RNeasy
Mini kit (Qiagen; Valencia, CA). The RNA samples
were treated with DNase I before reverse transcription
processing to remove genomic DNA contamination. A
total of 2 mg RNA from each sample was reverse tran-
scribed into cDNA with the SuperScript III first-strand
synthesis system (Invitrogen; Carlsbad, CA) according
to the manufacturer’s suggested protocol. The expres-
sion of candidate gene mRNAwas measured by SYBR
green real-time PCR using an ABI 7300 instrument
(Applied Biosystems; Foster, CA). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), a housekeeping
gene, was used as an internal control. The specific forward
primer 5′-GGAGCTGACTTCGGAACTAAAGG-3′
and reverse primer 5′-TGTGGTTTTCAGGGAGG-
CC-3′ for LCN2 was used. The PCR was performed


























primer, and power SYBR green PCR master mix
(Applied Biosystems). The thermal cycling conditions
consisted of a preincubation for 2 min at 50C and de-
naturation for 10 min at 95C, followed by 40 cycles of
denaturation for 15 sec at 95C and annealing/extension
for 1 min at 60C. All experiments were done in triplicate
to verify the results. The normalization formula was as
follows: target amount 5 22DDCt, where DDCt 5 [Ct
(Candidate gene) 2 Ct (Candidate gene GAPDH)] 2
[Ct (HOSE186) 2 Ct (HOSE 186 GAPDH)].
IHC
The paraffin-embedded specimens used in this study
were archived tissue samples and not from patients
contributing fresh specimens and consisted of tissue
from 10 healthy ovaries, 11 mucinous cystadenomas,
9 borderline ovarian tumors (5 serous and 4 mucinous),
and 61 epithelial ovarian cancers (38 serous, 12 mucin-
ous, 6 endometrioid, 2 transitional cell, 2 mixed, and
1 clear cell).
IHC studies were performed using the avidin-biotin
technique with the LSAB1 System-HRP (DakoCyto-
mation; Glostrup, Denmark). Paraffin sections were
deparaffinized in xylene, rehydrated in graded ethanol,
and treated for 10 min with 3% H2O2 in methanol to
block endogenous peroxidase. Sections were incubated
in a moist chamber with primary anti-human LCN2
goat IgG (5 mg/ml; R&D Systems, Minneapolis, MN)
for 30 min at room temperature, followed by incubation
with biotinylated secondary antibody (DakoCytomation)
for 30 min. The reaction product was visualized using a
DAB chromogen solution (DakoCytomation). Sections
were counterstained with hematoxylin and mounted in
Paramount aqueous mounting medium (DakoCytoma-
tion). Representative photomicrographs were recorded
using a digital camera (Nikon; Tokyo, Japan).
To evaluate IHC expression of LCN2, we applied a
four-grade scoring system corresponding to the sum of
staining intensity (0 5 negative; 1 5 weak; 2 5 mod-
erate; 3 5 strong) and the percentage of positive cells
(05 0%; 151–25%; 25 26–50%; 35 51–100%posi-
tive cells), as described elsewhere (Shibusa et al. 1998).
Slides were scored in the absence of any clinical data,
and the final immunostaining score was the average
score of two observers.
ELISA
Serum LCN2 level was quantified with a solid phase
sandwich ELISA using the Human Lipocalin-2/NGAL
Immunoassay kit (R&D Systems). Serum used in this
assay was derived from 90 healthy controls, 53 pa-
tients with benign tumors (19 mucinous cystadenomas,
16 mature teratomas, 7 serous cystadenomas, 5 endo-
metriotic cysts, 3 tubo-ovarian abscesses, and 3 hemor-
rhagic corpus luteal cysts), 15 patients with borderline
ovarian tumors (10 mucinous and 5 serous), and 54 pa-
tients with epithelial ovarian cancers (38 serous, 9 mu-
cinous, 4 clear cell, and 3 endometrioid).
Microplates were precoated with rat anti-LCN2
monoclonal antibody (100 ml of 20 mg/ml in 0.1 M
carbonate buffer; pH, 9.5) and blocked with 1% BSA
and 0.05% Tween 20. Serum and 640 ng/ml (9850 pM)
of human LCN2 standard were diluted with Calibrator
Diluent RD5-25 (provided by the manufacturer) and
added to the plates for 2 hr at 4C. After four washes
with diluted wash buffer, a volume of 200 ml horserad-
ish peroxidase conjugated to anti-LCN2 monoclonal
antibody was added and incubated for 2 hr at 4C. After
four additional washes, color reagents A (hydrogen per-
oxide) and B (tetramethyl benzidine) were added, and
the signal was allowed to develop for 30 min at room
temperature. The reaction was stopped with 50 ml of
1 N sulfuric acid, and the absorbance at 450 nm was
measured by an automatic ELISA reader.
Results were converted from mean absorbance of
duplicate wells after subtraction of background values.
Recombinant human LCN2 protein (R&D Systems)
was used as a standard. The standard curve was pre-
pared simultaneously with the measurement of test
samples. A reagent blank, a test sample blank, and in-
ternal controls of serum samples were used to normal-
ize LCN2 values obtained from each experiment.
Statistical Analysis
Relative serum LCN2 levels were compared using
an unpaired t-test on log-transformed values. Serum
LCN2 levels ranged over multiple orders of magnitude;
thus, a logarithmic transformation was used to change
the data to an arithmetic scale. The transformed data
complied more accurately with the assumption of a
Gaussian distribution for residuals in general linear
models. Data were summarized based on the number
of observations, the geometric mean [p values were ap-
plied appropriately to differences in the log (LCN2)
levels], the 95% CI for the geometric mean, and the
range of the data.
Comparison of groups was performed using the
Mann-Whitney U test, one-way ANOVA, and Kruskal-
Wallis tests where appropriate. To report specificity and
sensitivity estimates, we used full receiver operating
characteristics (ROC) curves with cut-off values that
maximized the sum of sensitivity and specificity. The
Cox proportional hazards model was used to determine
the prognostic significance of the variables for pre-
dicting overall and disease-free survival. Predictive vari-
ables were selected by stepwise (forward and backward)
selection procedures. All statistical tests were two sided,
and significance was defined at a level of p,0.05. Statis-
tical analyses were performed using SPSS version 12.0
(SPSS; Chicago, IL).


























SYBR Green Real-time PCR Analysis of LCN2
To study variation in transcript LCN2 levels, SYBR
green real-time PCR analysis was applied to an ex-
panded series of epithelial ovarian cancer cell lines,
cancer tissues, and borderline ovarian tumor tissues
(Figure 1). The mean 22DDCt value of borderline tu-
mors (615-fold), cancer cell lines (4727-fold), and can-
cer tissues (1058-fold) was significantly higher than
that of healthy HOSE cells (p50.042). Except for
TOV112D, the other 10 ovarian cancer cell lines had
the higher levels of LCN2. There was no significant dif-
ference in LCN2 expression among the tumor tissues of
different histological subtypes.
IHC
The mean ages of women involved in the IHC study
were 53 years for those with ovarian cancer, 45 years
for those with borderline ovarian tumors, and 37 years
for those with benign ovarian tumors. LCN2 immuno-
reactivity was not evident in normal ovarian surface
epithelium. However, 98.3% (60/61) of ovarian can-
cers, 100% (9/9) of borderline ovarian tumors, and
72.7% (8/11) of benign ovarian tumors stained posi-
tive for LCN2. Most staining was observed in the
cytoplasm of tumor cells (Figure 2).
The immunostaining scores from healthy ovaries,
benign ovarian tumors, borderline ovarian tumors,
and epithelial ovarian cancers were 0.00 (95% CI,
0.00–0.00), 2.36 (95% CI, 1.36–3.36), 3.38 (95% CI,
2.41–4.36), and 4.44 (95% CI, 4.09–4.78), respec-
tively (Table 1). Differences between diagnostic groups
(p,0.001) and differences between tumor grades
(p50.002) were statistically significant, with well-
differentiated cases having higher staining scores (Fig-
ure 3). For those with ovarian cancers, there was no
significant difference in LCN2 immunoreactivity among
different stages or histological types.
Pretreatment Serum LCN2 Levels in Patients With
Ovarian Cancer
In real-time PCR and IHC, we found that LCN2 was
overexpressed in borderline and malignant tumors but
very weakly expressed in benign tumor tissues. There-
fore, we next examined the LCN2 levels in the pretreat-
ment serum samples using a solid phase sandwich
ELISA. FIGO staging was available for all 54 ovarian
cancer cases. There were 5 Stage I samples, 3 Stage II
samples, 38 Stage III samples, and 8 Stage IV samples
from epithelial ovarian cancers included in the ELISA
studies. The mean ages for the groups by diagnostic cat-
egory were 50.3 years for healthy controls, 39.2 years
for patients with benign ovarian tumors, 37.7 years for
patients with borderline ovarian tumors, and 52.6 years
for patients with ovarian cancers. Because the age
difference between the study group was significant
Figure 1 Relative quantitation of lipocalin2 (LCN2) in healthy ovarian epithelial cell cultures, borderline ovarian tumor tissues, ovarian cancer
cell lines, and cancer tissues. Independent t-tests showed statistically significant differences between study groups (p,0.001). Each value is


























(p50.001), p values for the differences in mean LCN2
levels are presented from linear models that include a
term for age.
In healthy controls, the mean serum LCN2 level was
61.9 ng/ml (95% CI, 29.3–121.6). The corresponding
LCN2 values were 67.1 ng/ml (95% CI, 14.3–238.2)
for patients with benign ovarian tumors, 72.1 ng/ml
(95% CI, 33.2–111.0) for patients with borderline
ovarian tumors, and 87.4 ng/ml (95% CI, 67.5–107.3)
for patients with ovarian cancers. Serum LCN2 levels
were significantly higher in ovarian cancer patients com-
pared with healthy controls (p50.012). We also com-
pared the relationship of serum LCN2 and CA125
levels with clinicopathological characteristics in ovarian
cancer patients (Table 2). There were significant differ-
ences in LCN2 levels among tumor grade (p50.038)
and histological type (p50.001) of ovarian cancer, with
well-differentiated tumors and mucinous cases having
higher LCN2 expression (Figure 4). However, serum
CA125 levels did not correlate with these clinicopatho-
logical characteristics.
Diagnostic and Prognostic Significance of Serum
LCN2 Levels
The ROC curve was used to analyze the ability of
LCN2 to identify patients with ovarian cancer for
all possible cut-off values. The area under the curve
(AUC) for serum LCN2 levels in ovarian cancer pa-
tients was 0.622 (95% CI, 0.526–0.717). On the basis
of an optimal cut-off value (55.2 ng/ml) that maxi-
mized the sum of sensitivity and specificity in the
ROC curve, the sensitivity and specificity of serum
LCN2 level for detecting ovarian cancer was 72.2%
and 50.4%, respectively. For CA125, a fixed cut-off
value of 35 U/ml was used for the analysis of diagnostic
power. The AUC for CA125 was 0.917 (95% CI,
0.873–0.960), with a sensitivity of 79.6% and specific-
ity of 79.1%.
Table 1 Expression of LCN2 in relation to clinicopathological
characteristics in IHC analysis
Scores
No. of patients Geometric mean (95% CI) Range
All study subjects 91 3.59 (3.19–4.00) 0.0–6.0
Diagnostic category
Healthy 10 0.00 (0.00–0.00) 0.0–0.0
Benign 11 2.36 (1.36–3.36) 0.0–4.5
Borderline 9 3.38 (2.41–4.36) 2.0–5.5
Cancer 61 4.44 (4.09–4.78) 0.0–6.0
p value ,0.001
FIGO stage of cancer
I/II 13 4.15 (3.47–4.83) 2.5–6.0
III/IV 44 4.48 (4.04–4.92) 0.0–6.0
Recurrence 4 4.87 (3.51–6.23) 4.0–6.0
p value 0.597
Histology of cancer
Serous 38 4.43 (4.00–4.86) 0.0–6.0
Mucinous 12 4.54 (3.55–5.53) 1.0–6.0
Endometrioid 6 4.08 (2.65–5.50) 2.0–6.0
Others 5 4.70 (2.80–6.59) 2.0–5.5
p value 0.885
Grade of cancer
Borderline 9 3.38 (2.41–4.36) 2.0–5.5
Well 9 5.05 (4.16–5.94) 3.0–6.0
Moderate 21 4.80 (4.41–5.20) 2.5–6.0
Poor 26 3.92 (3.26–4.58) 0.0–6.0
p value 0.009
The Kruskal-Wallis ANOVA was used to compare the staining score among
the groups. LCN2, lipocalin2; FIGO, International Federation of Gynecology
and Obstetrics.
Figure 2 Evaluation of LCN2 IHC staining. The staining intensity (A, no evidence of staining, 0; B, weak staining, 11; C, moderate staining,
21; D, strong positive staining in most cells, 31) and the percentage of positive cells (E, no cells staining positive, 0; F, ,25% of cells staining
positive, 11; G, 25%–50% of cells staining positive, 21; H, .50% of cells staining positive, 31) were scored. Representative fields were photo-
graphed in serous type. Bars: A–D 5 50 mm; E–H 5 100 mm.

























Clinicopathological and outcome information and
marker values for LCN2 and CA125 were available
for 50 ovarian cancer patients who were monitored
for survival and recurrence. The mean follow-up time
was 22.1 months. Nine patients (18.0%) died within this
period, 12 (24.0%) survived but suffered recurrence,
4 (8.0%) survived but suffered persistent disease, and
25 (50.0%) showed no evidence of disease after treat-
ment. For the patients with recurrent disease, the mean
time to recurrence after initial treatment was 14.6 months.
Cox proportional hazards analysis was performed
to compare the impact of LCN2 expression on survival
Table 2 Pretreatment serum levels of LCN2 and CA125 in ovarian cancer patients
LCN2 level (ng/ml) CA125 level (U/ml)
No. of patients Geometric mean (95% CI) Range Geometric mean (95% CI) Range
All study subjects 212 70.4 (63.8–77.0) 14.3–414.3 239.6 (138.1–341.0) 5.2–6899.5
Diagnostic category
Healthy 90 61.9 (57.2–66.5) 29.3–121.6 13.6 (12.3–14.9) 5.2–41.1
Benign 53 67.1 (55.4–78.7) 14.3–238.2 32.9 (21.6–44.2) 6.3–215.5
Borderline 15 79.6 (40.2–119.0) 27.8–281.7 272.2 (4.8–539.7) 12.2–1482.0
Cancer 54 87.4 (67.5–107.3) 21.1–414.3 810.6 (454.9–1166.3) 9.9–6899.5
p value 0.021 ,0.001
FIGO stage of cancer
I/II 8 72.5 (41.2–103.9) 32.1–151.0 243.0 (2237.3 to 723.3) 9.9–1663.0
III/IV 46 90.0 (67.0–113.0) 21.1–414.3 909.3 (502.0–1316.7) 25.9–6899.5
p value 0.536 0.184
Histology of cancer
Serous 38 72.8 (62.9–82.7) 21.8–147.9 997.9 (532.6–1463.2) 14.0–6899.5
Mucinous 9 167.1 (53.2–281.0) 32.1–414.3 472.8 (2413.3 to 1359.1) 9.9–3539.5
Others 7 64.6 (42.1–87.0) 35.8–103.8 227.9 (235.9 to 491.9) 25.9–825.0
p value 0.001 0.252
Grade of cancer
Borderline 15 79.6 (40.2–119.0) 27.8–281.7 272.2 (4.8–539.7) 12.2–1482.0
Well 6 155.7 (7.7–303.6) 49.1–414.3 1027.6 (2728.1 to 2783.3) 124.0–3539.5
Moderate 23 79.3 (63.7–95.0) 21.1–151.0 807.3 (326.5–1288.1) 9.9–4141.0
Poor 25 78.5 (49.1–108.0) 29.9–401.1 771.8 (175.2–1368.4) 14.0–6899.5
p value 0.038 0.495
The Kruskal-Wallis ANOVA and the Mann-Whitney U test was used to compare the serum LCN2 level among the groups. LCN2, lipocalin2; FIGO, International
Federation of Gynecology and Obstetrics.
Figure 3 IHC staining score of LCN2 in ovarian cancer samples. (A) IHC staining score of LCN2 in ovarian cancer samples was significantly
higher than that in benign ovarian tumors and healthy controls. (B) The mean scores associated directly with tumor grade; well-differentiated
tumors stained more strongly than poorly differentiated tumors. The Kruskal-Wallis ANOVA and a post hoc Dunn method were used to


























with those of currently used clinicopathological prog-
nostic factors (CA125, age, stage, grade, and histologi-
cal type). On univariate Cox survival analysis, we found
thatLCN2 (hazard ratio51.47,p50.012),CA125 (haz-
ard ratio 5 2.46, p50.041), and stage (hazard ratio 5
3.46, p50.017) were significantly associated with over-
all survival. However, no variables were independent
predictors of poor prognosis on multivariate analysis.
Discussion
In this study, we validated the use of LNC2 as a poten-
tially relevant ovarian cancer serum biomarker. LCN2
was identified in our previous study as being upregu-
lated in ovarian cancer cell lines using cDNA micro-
arrays. In this study, we examined the potential of
LCN2 as a novel biomarker using SYBR green real-
time PCR in normal and ovarian cancer cell lines and
in ovarian cancer tissues. We also used IHC to study
LCN2 expression in cancer and normal tissues. Finally,
we measured and compared the LCN2 levels in sera
from healthy controls and case patients with ovarian
cancers, borderline ovarian tumors, and benign ovarian
tumors. We showed that serum LCN2 levels were signif-
icantly elevated in our cohort of ovarian cancer patients.
Although LCN2 was identified more than a decade
ago, the physiological functions of this protein remain
poorly understood. LCN2 is the human homolog of
the murine molecule known as oncogene 24p3 (mouse)
and neu/HER2-related lipocalin (rat) (Hraba-Renevey
et al. 1989). LCN2 is released from activated neutrophils
and exists in monomeric and homo- and heteromeric
forms; the latter forms a dimer with human neutrophil
gelatinase B (pro-MMP-9) (Kjeldsen et al. 1993).Anum-
ber of functions have been postulated for LCN2. For in-
stance, LCN2 is involved in the inflammatory response,
and high concentrations of LCN2 expression are found
in tissues that are often exposed to microorganisms, in-
dicating a role for this protein in the defense against
bacteria (Xu and Venge 2000). Chronic inflammation
was recently recognized as a risk factor for epithelial-
derived malignancies (Brower 2005). In a previous
study on the inflammatory response in epithelial ovar-
ian cancer, we found that the neutrophil count was sig-
nificantly elevated in ovarian cancers (Cho et al. 2009).
As cancer and inflammation are related, it is reasonable
to expect an upregulation of LCN2 expression in pre-
malignant and early-stage ovarian malignancies when
the inflammatory process is heightened. LCN2 also
serves as an iron-transporting protein (Yang et al.
2002). Because iron is a component of enzymes involved
in DNA synthesis, metabolism, oxygen response, and
regulation of gene expression at the transcriptional
and post-transcriptional level, the delivery of iron to
cells is crucial for development, cell growth, and sur-
vival (Cooper and Porter 1997). In addition, abnormal
expression of LCN2 has been shown in several types
of cancers including colon, pancreas, and breast can-
cer (Nielsen et al. 1996; Stoesz et al. 1998; Moniaux
et al. 2008).
In this study, we showed, through SYBR green real-
time PCR, that LCN2 mRNA expression is increased
in ovarian cancer cell lines, ovarian cancer tissues,
and borderline ovarian tumor tissues compared with
healthy ovarian surface epithelial cells (p,0.001).
With the exception of only 1 ovarian cancer cell line,
TOV112D, the other 10 ovarian cancer cell lines and
7 ovarian cancer tissues had significantly higher
LCN2 levels than the HOSE cell lines. The TOV112D
comes from a Grade 3 ovarian endometrioid tumor,
and the histological type may reflect the low expression
of LCN2 in the TOV112D cell line, because endo-
metrioid cell types had significantly lower LCN2 ex-
pression than other histological types by real-time
PCR, IHC, and ELISA. Although the mechanisms un-
derlying histological type-specific expression of LCN2
are unclear, endometrioid tumors display morphologi-
cal and molecular genetic alterations that are different
from those seen in other types of ovarian tumors, and it
may be different expression of LCN2. Furthermore, the
small number of patients with endometrioid tumors in
this study may have influenced the results.
To further validate LCN2 expression in actual tu-
mor tissues, we examined the LCN2 expression by
IHC staining. We observed the immunoreactivity ex-
clusively in tumor cells (60 of 61 cases, 98.3%). Signifi-
cantly stronger cytoplasmic staining was detected in
cancer tissues than in benign ovarian tumors (p,0.001)
and healthy ovarian tissues (p,0.001). Normal ovarian
epithelia and ovarian stroma were negative for LCN2
Figure 4 Pretreatment serum LCN2 levels in study subjects. The dif-
ferences in diagnostic categories were statistically significant
(p50.021), as were the differences in tumor differentiation
(p50.038). The Kruskal-Wallis ANOVA and a post hoc Dunn method
were used to compare the serum LCN2 level among the groups.

























expression. These results strongly suggest that the
source of elevated serum LCN2 level in ovarian cancer
is the cancer tissue itself. IHC results also showed a
grade-specific pattern of LCN2 expression. It has been
previously reported that LCN2/NGAL expression cor-
related strongly with poor histological grade in the IHC
study of breast cancer patients (Bauer et al. 2008).
However, in our study, significantly increased LCN2
immunoreactivity was observed in well-differentiated
ovarian tumors compared with moderately and poorly
differentiated tumors (Table 1; Figure 3). Furthermore,
these immunostaining data correlated with the ELISA
results of this study. Partly consistent with the this
study, Lim et al. (2007) reported that LCN2 expressions
were evident in borderline and Grade 1 ovarian tumors
and explored the clinical usefulness of LCN2 as a marker
of premalignant lesions in ovarian cancer. Moniaux
et al. (2008) also found a gradient of LCN2 expression
in pancreatic tumors, from the strongest staining in
well-differentiated tumors to no staining in poorly
differentiated tumors. Our study suggests that well-
differentiated epithelial ovarian cancers stain intensely
for LCN2 and that such staining reliably reflects the
amount of epithelial differentiation. LCN2 expression
is linked with the epithelial phenotype of ovarian tu-
mors and is lost as cancer progresses and epithelial
tumors become poorly differentiated.
For tumor marker discovery, it is essential to show
that changes in mRNA expression are reflected at the
protein level and that these proteins are shed into body
fluid where they can be sampled conveniently. To de-
termine whether the profile of LCN2 expression found
in tissues was reflected in peripheral blood, we exam-
ined serum LCN2 level by ELISA from patients with
ovarian cancer, borderline ovarian tumors, benign
ovarian tumors, and from control subjects. LCN2 serum
levels in ovarian cancers were significantly higher than
those of other study groups (p50.021). In addition,
LCN2 serum levels were significantly higher in the pa-
tients with well-differentiated tumors than other grades
of tumors (p50.038), which is consistent with the IHC
analysis. When analyzed in according to the histologi-
cal subtypes, LCN2 serum levels in mucinous-type tu-
mors (167.1 ng/ml) were considerably higher than in
other histological types (serous: 72.8 ng/ml, other types:
64.6 ng/ml). The molecular basis for this observation
is unclear but may reflect fundamental differences in
histogenesis between non-mucinous and mucinous
ovarian carcinomas. Several published studies have re-
ported molecular differences in mucinous and serous
type ovarian cancer and suggested that mucinous tu-
mors should be regarded as separate entities (Pieretti
et al. 2002; Fujita et al. 2003). Several biomarkers, such
as mesothelin and N-cadherin, have been found to
show differing expression between non-mucinous and
mucinous ovarian cancers (Peralta Soler et al. 1997;
Ordonez 2003). We also suspected that this discrepancy
between IHC and ELISA result could be because of
the fact that the samples were from a different cohort
of patients.
Finally, we analyzed the diagnostic and prognostic
power of LCN2 serum levels and found that serum
levels of this protein may be a useful discriminative
marker for ovarian cancer. However, the approximate
area under the ROC curve for LCN2 as an indepen-
dent diagnostic tool for ovarian cancer detection was
0.622, which was inferior to that of CA125, suggesting
that LCN2 alone is unlikely to be sufficiently sensitive
to detect all cases of ovarian cancer. Furthermore, no
variables were independent predictors of poor prog-
nosis by Cox proportional multivariate analysis. Never-
theless, a large study with more cases and controls
needs to be performed to confirm the clinical relevance
of LCN2 in combination with CA125 or other potential
tumor markers. Considering the heterogeneity of ovar-
ian cancers from different patients, it is unlikely that
any single marker will be sufficiently sensitive to pro-
vide an optimal initial screen. Adding one or several
markers to CA125 for use as a combined marker could
improve diagnostic performance if sensitivity were im-
proved with no loss in specificity.
Gene expression analysis has the potential to guide
the treatment of ovarian tumors, help diagnose the
subtypes of disease, and predict the patient survival.
Our study provides a case of validation, which is neces-
sary once a differentially expressed gene has been iden-
tified through microarray analysis. We report that
serum LCN2 levels may serve as a possible circulating
biomarker for epithelial ovarian cancers. Future studies
are needed to assess whether serum LCN2 levels, either
alone or in combination with other markers, could be
used as a serum biomarker to improve the sensitivity
and specificity of identifying early-stage ovarian cancer
or subgroups of such cancers.
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